The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma
- PMID: 18376797
The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and its diagnosis on routine stains is usually straightforward, except in some cases where there may be difficulty in distinguishing HCCs from metastatic carcinomas (MC) and cholangiocarcinomas (CC). Hepatocyte Paraffin 1 antibody (Hep Par 1) is a new monoclonal antibody which reacts with normal and neoplastic hepatocytes, and this study aims to determine its specificity and sensitivity in distinguishing hepatocellular carcinoma (HCC) from cholangiocarcinoma (CC) and metastatic carcinomas (MC). Hep Par 1 antibody was applied to 28 cases of HCC, 22 cases of MC from varying sites and 8 CCs, and produced a strong, diffuse, granular, cytoplasmic staining of all benign hepatocytes. 23 out of 28 cases of HCC showed heterogeneously positive staining for Hep Par 1 irrespective of their degree of differentiation, while 2 out of 8 cases of cholangiocarcinoma were positive for Hep Par 1, and all 22 cases of metastatic carcinoma were negative. The sensitivity and specificity of Hep Par 1 for HCC was 82.1% and 93.3% respectively; whereby the antibody was noted to show occasional false positivity in cases of cholangiocarcinoma and non-neoplastic bowel mucosa, while its variable staining in HCC produced false negative results in some small biopsies. Thus, Hep Par 1 should be used in a panel with other antibodies to obtain useful information in distinguishing HCC from CC and MC.
Similar articles
-
Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors.Indian J Pathol Microbiol. 2006 Jul;49(3):341-4. Indian J Pathol Microbiol. 2006. PMID: 17001880
-
[Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):702-5. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 19173916 Chinese.
-
Immunohistological evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1.J Surg Oncol. 2004 Nov 1;88(2):104-7. doi: 10.1002/jso.20144. J Surg Oncol. 2004. PMID: 15499598
-
[Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].Zentralbl Chir. 2007 Aug;132(4):300-5. doi: 10.1055/s-2007-981195. Zentralbl Chir. 2007. PMID: 17724632 Review. German.
-
Management of combined hepatocellular and cholangiocarcinoma.Int J Clin Pract. 2008 Aug;62(8):1271-8. doi: 10.1111/j.1742-1241.2007.01694.x. Epub 2008 Feb 13. Int J Clin Pract. 2008. PMID: 18284443 Review.
Cited by
-
Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.Pathol Oncol Res. 2015 Apr;21(2):379-87. doi: 10.1007/s12253-014-9830-6. Epub 2014 Aug 10. Pathol Oncol Res. 2015. PMID: 25108409
-
The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1.Diagn Pathol. 2012 Oct 30;7:149. doi: 10.1186/1746-1596-7-149. Diagn Pathol. 2012. PMID: 23111165 Free PMC article.
-
Perihilar clear cell cholangiocarcinoma: an often-diagnostic challenge.BMJ Case Rep. 2020 Dec 22;13(12):e237683. doi: 10.1136/bcr-2020-237683. BMJ Case Rep. 2020. PMID: 33370986 Free PMC article.
-
Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis.Oncologist. 2019 Jul;24(7):997-1007. doi: 10.1634/theoncologist.2018-0268. Epub 2019 Mar 25. Oncologist. 2019. PMID: 30910867 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical